InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,436.44
(
-0.50%
)
US TECH 100
18,569.20
(
1.46%
)
Dow Jones
40,743.33
(
0.50%
)
Brent Oil
80.12
(
1.97%
)
Bitcoin
65,964.17
(
-0.31%
)
Post# of 43164
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

nonebass

Send PM Follow Ignore
Followers 1
Posts 9
Boards Moderated 0
Alias Born 10/18/2020

nonebass

Re: None

Wednesday, 03/03/2021 2:24:27 AM

Wednesday, March 03, 2021 2:24:27 AM

Post# of 43164
Assuming a positive phase 3 top line...

If BET-B's suspension of recruitment is not a mistake...

Considering what was said at the recent Humangen conference (Expected: 9 days for placebo vs. remdesivir, 6 days for placebo versus lenses for recovery / After clinical start: The expected recovery period for remdesivir was shorter than expected. )

In connection with the Mayo Clinic's recommendation to make Lenz a standard treatment...

It is more efficient to use it as a monotherapy of Lenz than as a combination therapy in the BET-B trial. In other words, it is thought that a single standard treatment for Lenz is possible...

What do you guys think?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up